TY - JOUR
T1 - Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma
AU - Kudelka, A. P.
AU - Tresukosol, D.
AU - Edwards, C. L.
AU - Freedman, R. S.
AU - Levenback, C.
AU - Chantarawiroj, P.
AU - Gonzalez de Leon, C.
AU - Kim, E. E.
AU - Madden, T.
AU - Wallin, B.
AU - Hord, M.
AU - Verschraegen, C.
AU - Raber, M.
AU - Kavanagh, J. J.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1996/5
Y1 - 1996/5
N2 - Purpose: To determine the efficacy and toxicity of topotecan administered as a 5-day intravenous infusion in patients with advanced ovarian cancer refractory to cisplatin-based chemotherapy. Patients and Methods: Thirty patients with advanced epithelial ovarian cancer refractory to cisplatin- based chemotherapy received intravenous infusions of topotecan 1.5 mg/m2 delivered over 30 minutes each day for 5 days. A course was repeated every 21 days. The patient eligibility requirements included age > 18 years, Zubrod score ≤ 2, measurable disease, adequate hepatic and renal function, neutrophil count ≥ 1,500/μL, platelet count ≥ 100,000/μL, and anticipated survival ≥ 3 months. Results: Twenty eight patients were assessable for response and toxicity. All Patients were assessable for survival. The major toxicity from administration of topotecan at this dose schedule was myelosuppression; 21 patients required dose reductions. Four patients had neutropenic fever that required hospitalization, and seven patients required platelet transfusions. Maculopapular pruritic exanthema occurred in 20% of patients; gastrointestinal side effects were mild. No deaths were reported on the study. At dose levels of 1.5, 1.25, and 1.0 mg/m2, 61%, 31%, and 25% of patients, respectively, required dose reductions. Of 28 assessable patients, four (14%; 95% confidence interval [CI], 4% to 34%) achieved a partial response (PR) at a median of 1.4 months and lasting 8.9 months, and 17 had stable disease (SD). The overall median survival time was 10.0 months (95% CI, 8.1 to 13.5). Conclusion: Topotecan shows modest clinical activity against cisplatin-refractory ovarian cancer, although the dose-intensity is compromised by the depth of the granulocyte nadir and the duration of granulocytopenia. Further studies of topotecan may necessitate a reevaluation of optimal dose schedule, with the possible incorporation of multilineage cytokines, and its activity in taxane-resistant tumors.
AB - Purpose: To determine the efficacy and toxicity of topotecan administered as a 5-day intravenous infusion in patients with advanced ovarian cancer refractory to cisplatin-based chemotherapy. Patients and Methods: Thirty patients with advanced epithelial ovarian cancer refractory to cisplatin- based chemotherapy received intravenous infusions of topotecan 1.5 mg/m2 delivered over 30 minutes each day for 5 days. A course was repeated every 21 days. The patient eligibility requirements included age > 18 years, Zubrod score ≤ 2, measurable disease, adequate hepatic and renal function, neutrophil count ≥ 1,500/μL, platelet count ≥ 100,000/μL, and anticipated survival ≥ 3 months. Results: Twenty eight patients were assessable for response and toxicity. All Patients were assessable for survival. The major toxicity from administration of topotecan at this dose schedule was myelosuppression; 21 patients required dose reductions. Four patients had neutropenic fever that required hospitalization, and seven patients required platelet transfusions. Maculopapular pruritic exanthema occurred in 20% of patients; gastrointestinal side effects were mild. No deaths were reported on the study. At dose levels of 1.5, 1.25, and 1.0 mg/m2, 61%, 31%, and 25% of patients, respectively, required dose reductions. Of 28 assessable patients, four (14%; 95% confidence interval [CI], 4% to 34%) achieved a partial response (PR) at a median of 1.4 months and lasting 8.9 months, and 17 had stable disease (SD). The overall median survival time was 10.0 months (95% CI, 8.1 to 13.5). Conclusion: Topotecan shows modest clinical activity against cisplatin-refractory ovarian cancer, although the dose-intensity is compromised by the depth of the granulocyte nadir and the duration of granulocytopenia. Further studies of topotecan may necessitate a reevaluation of optimal dose schedule, with the possible incorporation of multilineage cytokines, and its activity in taxane-resistant tumors.
UR - http://www.scopus.com/inward/record.url?scp=9244247616&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9244247616&partnerID=8YFLogxK
U2 - 10.1200/JCO.1996.14.5.1552
DO - 10.1200/JCO.1996.14.5.1552
M3 - Article
C2 - 8622071
AN - SCOPUS:9244247616
SN - 0732-183X
VL - 14
SP - 1552
EP - 1557
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 5
ER -